HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Riferminogene pecaplasmide.

Abstract
Sanofi-aventis is developing riferminogene pecaplasmide, a fibroblast growth factor 1 (FGF-1; NV1FGF) gene therapy for the treatment of peripheral arterial disorders (PAD) such as critical limb ischemia. Following intramuscular injection into an area of restricted blood flow, riferminogene pecaplasmide is taken up by muscle cells resulting in increased expression of FGF protein, which in turn promotes blood vessel growth. Riferminogene pecaplasmide is currently being evaluated in a randomized, double-blind, placebo-controlled phase III trial (TAMARIS) in patients with PAD in 32 countries, including the US, EU, Canada, Japan and Australia. This review discusses the development history and scientific profile of this new compound.
Authors
JournalAmerican journal of cardiovascular drugs : drugs, devices, and other interventions (Am J Cardiovasc Drugs) Vol. 10 Issue 5 Pg. 343-6 ( 2010) ISSN: 1175-3277 [Print] New Zealand
PMID20860417 (Publication Type: Journal Article, Review)
Chemical References
  • riferminogene pecaplasmide
  • Fibroblast Growth Factor 1
Topics
  • Clinical Trials as Topic
  • Fibroblast Growth Factor 1 (genetics, therapeutic use)
  • Genetic Therapy
  • Humans
  • Peripheral Arterial Disease (therapy)
  • Plasmids

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: